ValuEngine upgraded shares of Endocyte, Inc. (NASDAQ:ECYT) from a strong sell rating to a sell rating in a research report sent to investors on Monday morning.

Other analysts have also recently issued reports about the stock. Wedbush cut shares of Endocyte from an outperform rating to a neutral rating and reduced their price objective for the stock from $8.00 to $2.00 in a research note on Monday, June 5th. Zacks Investment Research cut shares of Endocyte from a hold rating to a sell rating in a research note on Monday, August 14th. Two equities research analysts have rated the stock with a sell rating, one has issued a hold rating and two have assigned a buy rating to the company’s stock. Endocyte currently has a consensus rating of Hold and an average target price of $7.00.

Endocyte (NASDAQ ECYT) traded down 1.23% during midday trading on Monday, reaching $5.63. 3,141,427 shares of the company traded hands. The stock’s market capitalization is $239.70 million. Endocyte has a 12 month low of $1.17 and a 12 month high of $6.55. The firm has a 50 day moving average of $1.81 and a 200-day moving average of $1.91.

Endocyte (NASDAQ:ECYT) last issued its quarterly earnings data on Tuesday, August 8th. The biopharmaceutical company reported ($0.28) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.25) by ($0.03). Endocyte had a negative return on equity of 32.68% and a negative net margin of 61,437.14%. The firm had revenue of $0.01 million during the quarter. During the same period last year, the firm earned ($0.25) EPS. Analysts forecast that Endocyte will post ($1.06) EPS for the current fiscal year.

TRADEMARK VIOLATION WARNING: This piece was originally posted by Watch List News and is owned by of Watch List News. If you are accessing this piece on another domain, it was copied illegally and reposted in violation of United States & international copyright laws. The correct version of this piece can be read at https://www.watchlistnews.com/valuengine-upgrades-endocyte-inc-ecyt-to-sell/1613402.html.

Institutional investors have recently modified their holdings of the company. Stifel Financial Corp lifted its stake in shares of Endocyte by 3.9% in the first quarter. Stifel Financial Corp now owns 45,353 shares of the biopharmaceutical company’s stock worth $112,000 after buying an additional 1,711 shares during the last quarter. Dimensional Fund Advisors LP lifted its stake in shares of Endocyte by 34.1% in the second quarter. Dimensional Fund Advisors LP now owns 98,313 shares of the biopharmaceutical company’s stock worth $147,000 after buying an additional 25,003 shares during the last quarter. Teachers Advisors LLC lifted its stake in shares of Endocyte by 17.1% in the fourth quarter. Teachers Advisors LLC now owns 65,119 shares of the biopharmaceutical company’s stock worth $166,000 after buying an additional 9,506 shares during the last quarter. Spark Investment Management LLC acquired a new stake in shares of Endocyte in the second quarter worth $177,000. Finally, LMR Partners LLP acquired a new stake in shares of Endocyte in the second quarter worth $196,000. Institutional investors and hedge funds own 28.80% of the company’s stock.

About Endocyte

To view ValuEngine’s full report, visit ValuEngine’s official website.

Receive News & Ratings for Endocyte Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Endocyte Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.